miRNA-205 Nanoformulation Sensitizes Prostate Cancer Cells to Chemotherapy.
The therapeutic application of microRNA(s) in the field of cancer has generated significant attention in research. Previous studies have shown that miR-205 negatively regulates prostate cancer cell proliferation, metastasis, and drug resistance. However, the delivery of miR-205 is an unmet clinical need. Thus, the development of a viable nanoparticle platform to deliver miR-205 is highly sought. A novel magnetic nanoparticle (MNP)-based nanoplatform composed of an iron oxide core with poly(ethyleneimine)-poly(ethylene glycol) layer(s) was developed. An optimized nanoplatform composition was confirmed by examining the binding profiles of MNPs with miR-205 using agarose gel and fluorescence methods. The novel formulation was applied to prostate cancer cells for evaluating cellular uptake, miR-205 delivery, and anticancer, antimetastasis, and chemosensitization potentials against docetaxel treatment. The improved uptake and efficacy of formulations were studied with confocal imaging, flow cytometry, proliferation, clonogenicity, Western blot, q-RT-PCR, and chemosensitization assays. Our findings demonstrated that the miR-205 nanoplatform induces significant apoptosis and enhancing chemotherapeutic effects in prostate cancer cells. Overall, these study results provide a strong proof-of-concept for a novel nonviral-based nanoparticle protocol for effective microRNA delivery to prostate cancer cells.
['Nagesh|Prashanth K B|PKB|0000-0003-3518-405X', 'Chowdhury|Pallabita|P|', 'Hatami|Elham|E|0000-0001-6776-4003', 'Boya|Vijaya K N|VKN|', 'Kashyap|Vivek K|VK|', 'Khan|Sheema|S|', 'Hafeez|Bilal B|BB|', 'Chauhan|Subhash C|SC|', 'Jaggi|Meena|M|', 'Yallapu|Murali M|MM|']
prostate cancer miR-205 docetaxel chemosensitivity and EMT